Premas Technologies welcomes collaborative ventures and is open to diverse agreements for advancing vaccine development. Connect with us to explore how together we can address the challenges of infectious diseases and create impactful solutions for global health. Our commitment to innovation aligns seamlessly with our open invitation for collaborative partnerships in vaccine development.

 

Explore collaboration possibilities through our flexible partnership models:

 

Modality 1: Mutli-Antigenic VLPs (up to 3-4 antigens per VLP). Deliverables are the fully developed VLP.

​

 

Modality 2: CircRNA-VLP: The CircRNA-VLP is an exciting new area of vaccine delivery where the CircRNA and VLP proteins may target the same infectious agent or dual modality.